CR11457A - Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos - Google Patents
Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismosInfo
- Publication number
- CR11457A CR11457A CR11457A CR11457A CR11457A CR 11457 A CR11457 A CR 11457A CR 11457 A CR11457 A CR 11457A CR 11457 A CR11457 A CR 11457A CR 11457 A CR11457 A CR 11457A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- same
- bradykinin antagonists
- hialuronic acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000003152 bradykinin antagonist Substances 0.000 title 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Se describen las composiciones farmaceuticas que contienen, como ingredientes activos, una mezcla de un polimero de acýdo hialuronico con un antagonista del receptor de bradiquia B2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002225A ITMI20072225A1 (it) | 2007-11-23 | 2007-11-23 | "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR11457A true CR11457A (es) | 2010-11-05 |
Family
ID=40314753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR11457A CR11457A (es) | 2007-11-23 | 2010-05-21 | Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9101627B2 (es) |
| EP (1) | EP2222275B1 (es) |
| JP (1) | JP5383695B2 (es) |
| KR (1) | KR101585868B1 (es) |
| CN (1) | CN101868225B (es) |
| AP (1) | AP2628A (es) |
| AR (1) | AR069407A1 (es) |
| AT (1) | ATE529096T1 (es) |
| AU (1) | AU2008328311B2 (es) |
| BR (1) | BRPI0820402A2 (es) |
| CA (1) | CA2706398C (es) |
| CL (1) | CL2008003475A1 (es) |
| CO (1) | CO6270301A2 (es) |
| CR (1) | CR11457A (es) |
| CY (1) | CY1112134T1 (es) |
| DK (1) | DK2222275T3 (es) |
| EA (1) | EA017626B1 (es) |
| EC (1) | ECSP10010153A (es) |
| ES (1) | ES2374861T3 (es) |
| GE (1) | GEP20125602B (es) |
| HN (1) | HN2010001037A (es) |
| HR (1) | HRP20110904T1 (es) |
| IL (1) | IL205860A (es) |
| IT (1) | ITMI20072225A1 (es) |
| MA (1) | MA31913B1 (es) |
| MX (1) | MX2010005484A (es) |
| MY (1) | MY148685A (es) |
| NI (1) | NI201000087A (es) |
| NZ (1) | NZ585514A (es) |
| PA (1) | PA8804801A1 (es) |
| PE (1) | PE20091422A1 (es) |
| PL (1) | PL2222275T3 (es) |
| PT (1) | PT2222275E (es) |
| RS (1) | RS52045B (es) |
| SI (1) | SI2222275T1 (es) |
| TN (1) | TN2010000215A1 (es) |
| TW (1) | TWI448292B (es) |
| UA (1) | UA97867C2 (es) |
| WO (1) | WO2009065507A2 (es) |
| ZA (1) | ZA201003586B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO131947A2 (ro) * | 2014-05-30 | 2017-06-30 | Nataliia Mykolaivna Derkach | Soluţie stabilizată bazată pe substanţe active, şi metodă de preparare a soluţiei stabilizate de substanţe active |
| CA2972212C (en) | 2014-12-26 | 2024-10-29 | Seikagaku Corporation | AGENT AND IMPROVEMENT OF SUBJECTIVE OCULAR SYMPTOMS AND ASSOCIATED METHOD |
| MX2020009824A (es) | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| CN112203642B (zh) | 2019-03-25 | 2025-03-07 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
| TW202615652A (zh) | 2020-01-23 | 2026-04-16 | 南韓商阿特根公司 | 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物 |
| US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
| WO2022031093A1 (ko) | 2020-08-07 | 2022-02-10 | (주)알테오젠 | 재조합 히알루로니다제의 생산 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635489B2 (en) * | 2001-05-18 | 2009-12-22 | Leneau Holdings, Llc | Ingestion of hyaluronic acid for improved joint health |
| ITMI20021247A1 (it) * | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
-
2007
- 2007-11-23 IT IT002225A patent/ITMI20072225A1/it unknown
-
2008
- 2008-11-07 TW TW097142981A patent/TWI448292B/zh not_active IP Right Cessation
- 2008-11-10 MY MYPI2010002358A patent/MY148685A/en unknown
- 2008-11-10 EP EP08853047A patent/EP2222275B1/en active Active
- 2008-11-10 ES ES08853047T patent/ES2374861T3/es active Active
- 2008-11-10 EA EA201000678A patent/EA017626B1/ru not_active IP Right Cessation
- 2008-11-10 US US12/743,891 patent/US9101627B2/en not_active Expired - Fee Related
- 2008-11-10 DK DK08853047.2T patent/DK2222275T3/da active
- 2008-11-10 CN CN2008801169202A patent/CN101868225B/zh not_active Expired - Fee Related
- 2008-11-10 WO PCT/EP2008/009451 patent/WO2009065507A2/en not_active Ceased
- 2008-11-10 HR HR20110904T patent/HRP20110904T1/hr unknown
- 2008-11-10 PT PT08853047T patent/PT2222275E/pt unknown
- 2008-11-10 MX MX2010005484A patent/MX2010005484A/es active IP Right Grant
- 2008-11-10 NZ NZ585514A patent/NZ585514A/en not_active IP Right Cessation
- 2008-11-10 JP JP2010534395A patent/JP5383695B2/ja not_active Expired - Fee Related
- 2008-11-10 AP AP2010005265A patent/AP2628A/xx active
- 2008-11-10 SI SI200830475T patent/SI2222275T1/sl unknown
- 2008-11-10 BR BRPI0820402-0A patent/BRPI0820402A2/pt not_active IP Right Cessation
- 2008-11-10 UA UAA201006127A patent/UA97867C2/ru unknown
- 2008-11-10 GE GEAP200811807A patent/GEP20125602B/en unknown
- 2008-11-10 AU AU2008328311A patent/AU2008328311B2/en not_active Ceased
- 2008-11-10 RS RS20110524A patent/RS52045B/sr unknown
- 2008-11-10 CA CA2706398A patent/CA2706398C/en not_active Expired - Fee Related
- 2008-11-10 AT AT08853047T patent/ATE529096T1/de active
- 2008-11-10 PL PL08853047T patent/PL2222275T3/pl unknown
- 2008-11-10 KR KR1020107011164A patent/KR101585868B1/ko not_active Expired - Fee Related
- 2008-11-19 PE PE2008001955A patent/PE20091422A1/es not_active Application Discontinuation
- 2008-11-21 CL CL2008003475A patent/CL2008003475A1/es unknown
- 2008-11-21 AR ARP080105077A patent/AR069407A1/es unknown
- 2008-11-21 PA PA20088804801A patent/PA8804801A1/es unknown
-
2010
- 2010-05-05 EC EC2010010153A patent/ECSP10010153A/es unknown
- 2010-05-06 CO CO10054082A patent/CO6270301A2/es active IP Right Grant
- 2010-05-14 TN TN2010000215A patent/TN2010000215A1/fr unknown
- 2010-05-19 NI NI201000087A patent/NI201000087A/es unknown
- 2010-05-20 HN HN2010001037A patent/HN2010001037A/es unknown
- 2010-05-20 ZA ZA2010/03586A patent/ZA201003586B/en unknown
- 2010-05-20 IL IL205860A patent/IL205860A/en not_active IP Right Cessation
- 2010-05-21 CR CR11457A patent/CR11457A/es unknown
- 2010-06-15 MA MA32913A patent/MA31913B1/fr unknown
-
2011
- 2011-11-30 CY CY20111101177T patent/CY1112134T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY32036A (es) | Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones | |
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| UY31124A1 (es) | Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842 | |
| CO6460772A2 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| ECSP12012042A (es) | Derivados de pirazol como inhibidores de jak | |
| CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
| GT201200321A (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
| PE20151437A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| MX375183B (es) | Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas. | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| CR20110599A (es) | Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos | |
| NI202000028A (es) | Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CR20170590A (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| UY32029A (es) | "derivados de pirazolo -[5.1-b] - oxazol, su prepraración, composiciones farmacéuticas que los contienen y aplicaciones" | |
| MX2019011545A (es) | Composiciones celulares y de andamio inyectables. | |
| PA8804801A1 (es) | Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos | |
| EA201300857A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| CO6321246A2 (es) | Compuestos novedosos activos como antagonistas de receptor muscarinico | |
| CL2012001759A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica. | |
| TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
| UY32410A (es) | Azetidinas como antagonistas del receptor de histamina3 | |
| CR20110021A (es) | Composiciones farmaceuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides, y su uso | |
| UA102010C2 (ru) | Комбинация активных ингредиентов, которая содержит нестероидное противовоспалительное лекарственное средство и производное колхикозида |